source
- FDA's new rare-disease framework faces first test with Capricor's Duchenne therapy decisionThe FDA announced a new "fit-for-purpose" rare disease framework that aims to evaluate therapies based on patient need and realistically attainable evidence. The first real test of the approach wi…
- Oura to buy AI virtual care firm Counsel Health for $625 million, expanding in-app health servicesOura, known for its smart ring and health tracking, announced it will acquire Counsel Health, an AI-driven virtual primary-care provider, for $625 million in cash. The acquisition is slated to clo…